Analysts Set The Cooper Companies, Inc. (NASDAQ:COO) Price Target at $117.00

The Cooper Companies, Inc. (NASDAQ:COO) has earned an average recommendation of “Moderate Buy” from the eleven research firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $117.00.

Several equities research analysts recently issued reports on COO shares. Citigroup dropped their price objective on Cooper Companies from $116.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, December 6th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research report on Friday, December 6th. Wells Fargo & Company boosted their price objective on Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a report on Friday, December 6th. Morgan Stanley lowered their target price on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th. Finally, StockNews.com cut shares of Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th.

Institutional Trading of Cooper Companies

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. lifted its position in Cooper Companies by 23.4% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,868 shares of the medical device company’s stock valued at $163,000 after buying an additional 354 shares during the period. B. Riley Wealth Advisors Inc. increased its stake in shares of Cooper Companies by 113.1% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 2,529 shares of the medical device company’s stock worth $221,000 after acquiring an additional 1,342 shares in the last quarter. Cetera Investment Advisers lifted its position in Cooper Companies by 6.3% during the 2nd quarter. Cetera Investment Advisers now owns 22,244 shares of the medical device company’s stock valued at $1,942,000 after acquiring an additional 1,309 shares during the period. Sanctuary Advisors LLC bought a new stake in Cooper Companies during the second quarter worth about $3,043,000. Finally, Czech National Bank grew its holdings in Cooper Companies by 7.1% in the third quarter. Czech National Bank now owns 40,562 shares of the medical device company’s stock worth $4,476,000 after purchasing an additional 2,688 shares during the period. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Cooper Companies Trading Down 1.8 %

Shares of COO opened at $93.57 on Monday. Cooper Companies has a fifty-two week low of $84.76 and a fifty-two week high of $112.38. The business has a 50-day moving average of $94.99 and a 200 day moving average of $99.73. The firm has a market cap of $18.67 billion, a P/E ratio of 47.98, a price-to-earnings-growth ratio of 2.45 and a beta of 1.00. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Thursday, December 5th. The medical device company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.04. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.03 billion. During the same quarter in the previous year, the firm posted $0.87 EPS. The business’s revenue for the quarter was up 9.8% compared to the same quarter last year. As a group, research analysts forecast that Cooper Companies will post 3.98 EPS for the current year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.